Study of the preventive effect of laftidine for chemotherapy-induced peripheral neuropathy in patients receiving paclitaxel

未提供0 个研究点目标入组 40 人开始时间: 2021年1月18日最近更新: 2025年4月14日

试验速览

暂无简介。

•1.The age at the time of obtaining consent is 18 years or older
•2.Patients with cytopathological or clinical diagnosis of non-small cell lung cancer
•3.Cases where surgical treatment, definitive radiation therapy, and chemoradiation therapy are not indicated (excluding palliative irradiation)
•4.Patients scheduled to be treated by the treatment including paclitaxel
•5.Patients scheduled to treated by carboplatin+paclitaxel therapy (batch) or carboplatin+paclitaxel (batch) +pembrolizumab therapy
•(or patients with Grade 2 or higher (CTCAE ver5.0.) CIPN by split paclitaxel)
•6.Patients who are not recieving anti-ulcer drugs or are receiving anti-ulcer drugs but are considered to be able to change to lafutidine
•7.Patients who can ingest orally
•8.Patients who can recieve informed consent

•1.Patients who receive paclitaxel as chemoradiotherapy
•2.Patients who are pregnant or breastfeeding
•3.Patients with a history of drug hypersensitivity or allergy to lafutidine
•4.Patients with a history of drug hypersensitivity or allergy to paclitaxel
•5.Patients with contraindications reg arding paclitaxel administration, such as those with a history of hypersensitivity to polyoxyethylene castor oil-containing preparations (eg, cyclosporine injection) or severe myelosuppression
•6.Patients with a history of severe drug hypersensitivity to other drug s
•7.Patients who have already taken anti-ulcer drugs and cannot chang e to lafutidine
•8.Patients who cannot judg e subjective symptoms related to peripheral neuropathy due to sympto
•ms by brain metastasis or neuropathy
•9.Patients originaly had Grade2(CTCAE ver5.0.) or higher peripheral neuropathy
•10.Patients judg ed to be inappropriate by doctor to safely carry out this reserch

Grade 2 or higher peripheral neuropathy

Common Terminology Criteria for Adverse Events(CTCAE) version 5.0.

发起方

未提供